世界卫生组织与瑞士启动全球病原体共享平台BioHub

世界卫生组织与瑞士签署谅解备忘录，正式启动首个WHO BioHub设施1。该设施位于瑞士施皮茨，将承担病原体的安全接收、测序、存储和分配任务1。BioHub系统旨在改善目前主要依靠国家间双边合作且效率低下的病原体共享模式，加强全球实验室之间的病原体快速共享1。

瑞士联邦委员Alain Berset表示，"瑞士支持WHO BioHub倡议初期阶段，提供必要的瑞士生物安全实验室基础设施"1。WHO总干事Tedros Adhanom Ghebreyesus指出，"BioHub系统是促进病原体信息流动的重要一步"1。

当前，WHO正在进行试点阶段，使用SARS-CoV-2及其变种测试共享的可行性1。根据计划，该系统将在2022年从SARS-CoV-2扩展至其他病原体，并连接其他储存库和实验室网络1。该平台最终旨在为诊断、治疗和疫苗开发提供支持，以增强全球对新型病原体的防疫准备1。

The World Health Organization and Switzerland have signed a memorandum of understanding to establish the first WHO BioHub facility, a centralized system designed to streamline the international sharing of pathogenic samples1. Located in Spiez, Switzerland, the facility will safely receive, sequence, store, and prepare biological materials for distribution to laboratories worldwide1.

The initiative addresses critical inefficiencies in the current pathogen-sharing landscape, which relies primarily on bilateral agreements between nations and lacks systematic coordination1. By creating a coordinated hub, the BioHub system aims to accelerate the flow of pathogen information globally and strengthen pandemic preparedness capabilities1. WHO Director-General Tedros Adhanom Ghebreyesus described the system as "an important step in facilitating the movement of pathogen information"1. Swiss Federal Councillor Alain Berset emphasized Switzerland's commitment, stating that the country "supports the WHO BioHub initiative in its initial phase by providing the necessary Swiss biosafety laboratory infrastructure"1.

The BioHub is currently in a pilot phase, using SARS-CoV-2 and its variants to test the feasibility of sample sharing and analysis1. The system is planned to expand beyond SARS-CoV-2 to include other pathogens in 2022, with connections to additional storage facilities and laboratory networks1. The broader objective is to provide rapid access to pathogenic samples that can support diagnostic development, therapeutic research, and vaccine creation globally1.